Provided By GlobeNewswire
Last update: Dec 2, 2025
BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or “the Company”), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025.
Financial Highlights for the Nine Months Ended September 30, 2025
Business Highlights for the Nine Months Ended September 30, 2025
The Company has made significant progress in executing its strategic pivot and diversification strategy throughout 2025. Key initiatives and achievements demonstrating this progress include:
Management Commentary
Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, “The nine months ended September 30, 2025 represent an important period for NewGen, with net income of $17.5 million compared to a net loss in the prior year. This improvement was driven by our strategic focus on acquiring high-value intellectual property. The acquisition of Nodexus business including but not limited to advanced cytometry IP generated a bargain purchase gain and increased our net asset value per share to $66.75, positioning us as a technology-driven company with a licensing model that we can scale globally.”
“Beyond this core transformation, we embraced the execution of a diversified growth strategy across multiple high-potential sectors. Our digital asset initiatives include strategic Solana treasury positioning and exclusive tokenization mandates in art- and gold-backed assets, representing significant new revenue opportunities. Meanwhile, our UAE real estate joint venture provides direct access to promising Middle Eastern development projects with attractive revenue-sharing terms. Combined with our newly reinforced balance sheet, we believe this unique combination of proprietary technology assets, strategic market positioning, and strong execution creates compelling long-term value for our shareholders.”
Nine Months Ended September 30, 2025 Financial Results
About NewGenIvf Group Limited
NewGenIvf Group Limited (NASDAQ: NIVF) is a tech-forward, diversified, multi-jurisdictional company transforming industries through innovative solutions. The Company is strategically pivoting from its foundation in fertility services to a technology-driven model centered on the licensing of proprietary reproductive technologies. This core is augmented by strategic growth vectors in digital asset management, including tokenization services and a Solana treasury strategy, and real estate development through a joint venture in the UAE. NewGen is focused on building a high-growth, diversified ecosystem that leverages blockchain technology and strategic acquisitions to drive long-term shareholder value.
Safe Harbor Statements
This news release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook,” and similar statements. Forward-looking statements in this 6-K include, but are not limited to, statements regarding: (i) the Company’s strategic pivot to a technology-licensing business model and its ability to generate licensing revenue from acquired intellectual property; (ii) plans to invest in digital assets, including Solana, and the Company’s digital asset treasury strategy; (iii) tokenization services and revenue opportunities related to art collections and gold-backed assets; (iv) the anticipated benefits and revenue potential from the UAE real estate joint venture; (v) the potential reverse merger with SAXA, Inc and access to mining assets; (vi) the Company’s diversified growth strategy and ability to execute across multiple business sectors; and (vii) the Company’s financial condition, liquidity, and ability to fund its strategic initiatives.
These forward-looking statements are based on management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties, and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: (i) the Company’s ability to successfully commercialize and license acquired intellectual property; (ii) uncertainty regarding the actual fair value of acquired intangible assets and potential future impairment charges; (iii) risks that independent valuations may not reflect actual market value or revenue generating potential; (iv) regulatory requirements and restrictions affecting reproductive technologies in various jurisdictions; (v) extreme volatility in digital asset markets, including Solana; (vi) the Company’s limited operating history in multiple new business segments and unproven business models; (vii) management’s ability to effectively oversee business operations across multiple jurisdictions; (viii) uncertainties regarding the ability to fund, develop, obtain permits and complete the UAE real estate project; and (ix) the Company’s ability to secure additional financing on favorable terms or at all. The risks and uncertainties described above are not exhaustive. Additional risks and uncertainties not presently known to the Company may also adversely affect the Company’s business, financial condition, results of operations, and prospects. These factors may cause the Company’s actual results, performance, or achievements to differ materially from those in the forward-looking statements. Investors are urged to carefully review and consider the various disclosures made by the Company in this release and in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required under applicable law. Readers should not rely upon the information in this news release as current or accurate after its publication date.
For more information:
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
| NEWGENIVF GROUP LIMITED UNAUDITED CONSOLIDATED BALANCE SHEETS (Stated in US Dollars) |
||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (unaudited) | (audited) | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 295,289 | $ | 457,740 | ||||
| Accounts receivable, net | 185,907 | 49,245 | ||||||
| Inventories | 86,977 | 80,813 | ||||||
| Deposits, prepayments and other receivables, net | 951,046 | 195,446 | ||||||
| Deposit with a digital asset trading platform | 2,674,042 | 1,000,000 | ||||||
| Receivable from agents | 1,272,640 | 1,191,795 | ||||||
| Prepayments | --- | 197,706 | ||||||
| Due from related parties | 89,973 | — | ||||||
| Total current assets | 5,555,874 | 3,172,745 | ||||||
| Non-current assets | ||||||||
| Plant and equipment, net | 329,360 | 273,096 | ||||||
| Right-of-use assets, net | 846,335 | 98,570 | ||||||
| Intangible assets | 24,242,555 | --- | ||||||
| Investment in Artwork | 270,000 | --- | ||||||
| Financial Assets | 262,712 | |||||||
| Deferred legal and professional fees | 196,623 | --- | ||||||
| Other receivable, deposit and other receivables, net | 3,854,609 | 33,333 | ||||||
| Taxes recoverable | 326 | --- | ||||||
| Total non-current assets | 30,002,520 | 404,999 | ||||||
| TOTAL ASSETS | $ | 35,558,394 | $ | 3,577,744 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 797,718 | $ | 1,298,964 | ||||
| Accrued liabilities and other payables | 450,341 | 500,729 | ||||||
| Contract liabilities | 67,401 | 63,489 | ||||||
| Due to related parties | --- | 154,453 | ||||||
| Operating lease liabilities, current | 305,518 | 108,526 | ||||||
| Convertible notes | -- | 82,447 | ||||||
| Promissory note | -- | 500,000 | ||||||
| Taxes payable | -- | 11,746 | ||||||
| Total current liabilities | 1,620,978 | 2,720,354 | ||||||
| Non-current liabilities | ||||||||
| Operating lease liabilities, non-current | 298,081 | 10,231 | ||||||
| Convertible notes, non-current | 4,900,000 | 2,328,916 | ||||||
| Total non-current liabilities | 5,198,081 | 2,339,147 | ||||||
| Total liabilities | $ | 6,819,059 | $ | 5,059,501 | ||||
| Shareholders’ equity | ||||||||
| Ordinary shares, no par value, unlimited authorized shares and 430,540* and 2,030* shares issued and outstanding as of September 30, 2025 and December 31, 2024 respectively | — | — | ||||||
| Subscription receivable | — | (204,000 | ) | |||||
| Additional paid-in capital | 13,063,507 | 122,505 | ||||||
| Retained Earnings / (Accumulated deficit) | 16,562,336 | (985,994 | ) | |||||
| Accumulated other comprehensive (loss) income | (249,711 | ) | 18,875 | |||||
| Equity attributable to the shareholders of the Company | 29,376,132 | (1,048,614 | ) | |||||
| Non-controlling interests | (636,797 | ) | (433,143 | ) | ||||
| Total shareholders’ equity | 28,739,335 | (1,481,757 | ) | |||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 35,558,394 | $ | 3,577,744 | ||||
The accompanying notes are an integral part of these consolidated financial statements.
| * | The shares as presented have been adjusted retrospectively for Reverse Share Splits effected in February 2025 of 1 share for every 20 existing shares issued, in May 2025 of 1 share for every 10 existing share issued, in August 2025 of 1 share for every 5 shares issued and in December 2025 of 1 share for every 5 shares issued respectively. |
| NEWGENIVF GROUP LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (Stated in US Dollars) |
||||||||
| Nine Months Ended | ||||||||
| September 30, 2025 |
September 30, 2024 |
|||||||
| Revenues | $ | 3,301,879 | $ | 4,159,763 | ||||
| Cost of revenues | (2,870,058 | ) | (2,872,004 | ) | ||||
| Gross profit | 431,821 | 1,287,759 | ||||||
| Operating expenses | ||||||||
| Selling and marketing expenses | (494,388 | ) | (192,276 | ) | ||||
| General and administrative expenses | (5,690,300 | ) | (1,166,858 | ) | ||||
| Total operating expenses | (6,184,688 | ) | (1,359,134 | ) | ||||
| Operating income (loss) | (5,752,867 | ) | (71,375 | ) | ||||
| Other income (expenses), net | ||||||||
| Other income, net | 23,370,460 | 8,404 | ||||||
| Interest income | 2,003 | 2,399 | ||||||
| Interest expense | (173,583 | ) | (357,551 | ) | ||||
| Total other income (expenses), net | 23,198,880 | (346,748 | ) | |||||
| Income (loss) before taxes | 17,446,013 | (418,123 | ) | |||||
| Provision for income taxes | --- | --- | ||||||
| Net income (loss) | 17,446,013 | (418,123 | ) | |||||
| Less: net loss attributable to non-controlling interests | (102,317 | ) | (1,723 | ) | ||||
| Net income (loss) attributable to the shareholders of the Company | $ | 17,548,330 | (416,400 | ) | ||||
| Other comprehensive (loss) income | ||||||||
| Foreign currency translation adjustment | (369,923 | ) | 13,879 | |||||
| Total comprehensive income (loss) | 17,076,090 | (404,244 | ) | |||||
| Less: total comprehensive loss attributable to non-controlling interests | (203,654 | ) | 1,498 | |||||
| Total comprehensive income (loss) attributable to the shareholders of the Company | $ | 17,279,744 | (405,742 | ) | ||||
| Earning per share – basic | $ | 96.76 | (205.97 | ) | ||||
| Basic weighted average shares outstanding* | 180,304 | 2,030 | ||||||
The accompanying notes are an integral part of these consolidated financial statements.
| * | The shares as presented have been adjusted retrospectively for Reverse Share Splits effected in February 2025 of 1 share for every 20 existing shares issued, in May 2025 of 1 share for every 10 existing share issued, in August 2025 of 1 share for every 5 shares issued and in December 2025 of 1 share for every 5 shares issued respectively. |
NASDAQ:NIVF (12/3/2025, 11:40:38 AM)
1.3199
-0.18 (-12.01%)
Find more stocks in the Stock Screener


